Oracle announced that Oracle Health Sciences’ Clinical One platform has been selected by Servier to unify their clinical environment to start new trials in a more efficient way, make mid-study changes in real-time, and unite everyone working on a trial in a common data environment.
Servier has selected Clinical One for its shared capabilities and common functions, to unify its clinical environment, and save time on traditional clinical operations. Servier also chose Clinical One for its ability to address various aspects of decentralized trials. The platform will ensure data collection from new and multiple data sources, harmonize the data, and eliminate reconciliation by having a single source of truth, drawing valuable clinical insights via dashboards and KPIs.
Servier already uses Oracle Argus to process its safety cases.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.